The goal of the Melanoma SPORE Career Development Program is to develop an integrated cadre of investigators at all levels of training dedicated to translational research on human melanoma. The program will (1) recruit junior and senior physicians and basic scientists and support them to become competent translational investigators in the study of malignant melanoma, (2) provide in-depth training in basic science principles of cancer biology that are not commonly included in clinical fellowship training or Ph.D. programs, and (3) teach the fundamentals of the specific biology and clinical course of human melanoma to improve the ability of the awardees to conduct innovative translational research on this disease. The unique educational environment at M. D. Anderson and in the M. D. Anderson Melanoma Multidisciplinary Research Program will assure that these goals will be met. Three career development trainees (prefer 2 faculty and 1 fellow) will be supported annually. Solicitations will be made yearly for qualified candidates from within and outside of M. D. Anderson. The awardees will be reviewed and ranked by the SPORE Executive Committee and Internal Advisory Committee, with final decision made by the External Advisory Committee Renewals. Second years of support will also be contingent upon review by the Internal Advisory Committee. Our mentorship program includes nationally recognized clinical and laboratory translational investigators who will provide comprehensive training. The mentors have been selected from a diverse group of scientists and clinicians based on their interest in translational melanoma research and skill as educators, includes all senior SPORE faculty at Associate Professor or higher. The program will be evaluated annually, and the selection and training processes will be modified as required. Career Development will be maintained through out the term of the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA093459-01A1
Application #
6993459
Study Section
Special Emphasis Panel (ZCA1-GRB-V (O1))
Project Start
2004-07-09
Project End
2009-05-31
Budget Start
2004-07-09
Budget End
2005-05-31
Support Year
1
Fiscal Year
2004
Total Cost
$132,614
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
(2018) Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50:668-681
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Huckins, L M; Hatzikotoulas, K; Southam, L et al. (2018) Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol Psychiatry 23:1169-1180
Kim, Sun-Hee; Roszik, Jason; Cho, Sung-Nam et al. (2018) The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma. Clin Cancer Res :
Zhang, Tongwu; Choi, Jiyeon; Kovacs, Michael A et al. (2018) Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes. Genome Res 28:1621-1635
Velazquez-Torres, Guermarie; Shoshan, Einav; Ivan, Cristina et al. (2018) A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9:461
Cascone, Tina; McKenzie, Jodi A; Mbofung, Rina M et al. (2018) Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27:977-987.e4
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Teerlink, Craig C; Huff, Chad; Stevens, Jeff et al. (2018) A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma. J Natl Cancer Inst :
Bezrookove, Vladimir; Nosrati, Mehdi; Miller 3rd, James R et al. (2018) Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clin Cancer Res 24:4119-4125

Showing the most recent 10 out of 290 publications